February 1, 2018 / 6:49 AM / 20 days ago

Diabetes drugmaker Novo Nordisk Q4 operating profit slightly below expectations

COPENHAGEN, Feb 1 (Reuters) - Denmark’s Novo Nordisk , the world’s biggest maker of diabetes drugs, posted fourth-quarter operating profit slightly below expectations on Thursday and said it expects 2018 sales and operating profit measured in Danish crowns to be hit by a weaker dollar.

The firm posted a quarterly operating profit of 10.05 billion Danish crowns ($1.68 billion) on revenue of 27.99 billion crowns, down 10 percent from a year earlier and slightly below an average 10.38 billion crowns forecast in a Reuters poll of analysts. ($1 = 5.9976 Danish crowns) (Reporting by Jacob Gronholt-Pedersen; Editing by Sunil Nair)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below